Sharemaestro Newsreel

Is United Therapeutics Corp (UTHR) Overvalued After Q2 Earnings

Viatris (VTRS) Q2 Earnings on the Horizon: Analysts' Insights on Key Performance Measures

Viatris (VTRS) is expected to announce its Q2 earnings, with analysts predicting $0.62 per share and revenues of $3.68 billion, a 2.6% increase year-over-year. The consensus EPS estimate has seen a 1% downward revision in the past 30 days. Key metric forecasts include Net …

Journey Medical Corporation to Announce Second Quarter 2026 Financial Results on August 12, 2026

Journey Medical Corporation (Nasdaq: DERM) announced it will release its second quarter 2026 financial results after market close on Wednesday, August 12, 2026. The company will host a conference call and webcast on the same day at 4:30 p.m. ET to discuss the results …

Nine FDA-approved dermatology drugs: Journey Medical sets Aug. 12 call

Journey Medical Corporation (Nasdaq: DERM) announced it will release its second-quarter 2026 financial results after U.S. markets close on Wednesday, August 12, 2026. The company will host a conference call and live audio webcast on the same day at 4:30 p.m. ET to discuss …

Teknova AI lets developers configure custom reagents in minutes

Teknova (Nasdaq: TKNO) has launched Build-Tek™, an AI-powered configurator that allows therapeutic and diagnostic developers to design complex custom reagents and submit quote requests in minutes. This system guides users through various specifications, significantly reducing the time for quote generation from weeks to two …

RBC Adjusts Price Target on Pacira Biosciences to $25 From $24, Maintains Sector Perform Rating

RBC has increased its price target for Pacira Biosciences (PCRX) to $25 from $24, while maintaining a Sector Perform rating on the stock. This adjustment comes shortly after Pacira BioSciences reported its Q2 2026 earnings, posting an adjusted EPS of $0.73 per share against …

Aurora Cannabis stock gains after Q1 results (ACB:NASDAQ)

Aurora Cannabis (ACB) saw its stock rise in premarket trading after reporting its Q1 fiscal 2027 results. The Canadian cannabis company also projected sequential increases in revenue and adjusted EBITDA for the upcoming Q2.

Price to earnings forward of BioAge Labs, Inc. – SWB:Y7G

This article provides financial information for BioAge Labs, Inc. (SWB:Y7G), specifically focusing on its price-to-earnings forward metric. The content includes a brief mention of the period, value, and change associated with this financial indicator.

Amylyx Pharmaceuticals Inc expected to post a loss of 36 cents a share - Earnings Preview

Amylyx Pharmaceuticals Inc is projected to report a loss of 36 cents per share, according to a recent earnings preview. The article, sourced from Reuters via TradingView News, indicates this financial expectation for the company.

Lifecore Biomedical Q2 FY26 net loss widens to $6.2 million; revenue falls 6.2% to $34.2 million

Lifecore Biomedical reported a wider GAAP net loss of $6.2 million in Q2 FY26, with revenue decreasing by 6.2% to $34.2 million. GAAP gross profit also fell, and non-GAAP adjusted EBITDA saw a slight decrease. Despite these financial challenges, the company signed six new …

Earnings Flash (BCRX) BioCryst Pharmaceuticals, Inc. Reports Q2 Revenue $218.2M, vs. FactSet Est of $183.3M

BioCryst Pharmaceuticals, Inc. (BCRX) reported Q2 revenue of $218.2 million, significantly exceeding FactSet's estimate of $183.3 million. The company also updated its earnings guidance for the full year 2026 and announced increased Q2 earnings and revenue. Additionally, Wedbush adjusted BioCryst Pharmaceuticals' price target to …

Perrigo (NYSE:PRGO) Releases FY 2026 Earnings Guidance

United Therapeutics (NASDAQ:UTHR) Surprises With Q2 CY2026 Sales

Aurora Cannabis Announces Fiscal 2027 First Quarter Results

Aurora Cannabis Inc. reported its fiscal first quarter 2027 results, showing net revenue of $67.6 million and a 17% year-over-year increase in international medical cannabis net revenue. The company maintains a strong balance sheet with $149.1 million in cash and no debt, and recently …

Amylyx Pharmaceuticals earnings up next as trial data looms

Amylyx Pharmaceuticals is set to report Q2 earnings, with analysts anticipating narrowed losses but with primary focus on the imminent Phase 3 LUCIDITY trial data, expected in Q3 2026. The trial, evaluating avexitide for post-bariatric hypoglycemia, is considered a pivotal moment for the pre-revenue …

Kamada to Announce Second Quarter and First Half Ended June 30, 2026 Financial Results on August 12, 2026

Kamada (NASDAQ: KMDA; TASE: KMDA.TA) will release its financial results for the second quarter and first half ended June 30, 2026, before the U.S. market opens on Wednesday, August 12, 2026. The company will host a conference call on the same day at 8:30 …

Kamada Ltd. (NASDAQ: KMDA) sets August 12 call on Q2 2026

Kamada Ltd. (NASDAQ: KMDA) announced it will release its financial results for the second quarter and first half ended June 30, 2026, before the U.S. market opens on Wednesday, August 12, 2026. The biopharmaceutical company will host an investment community conference call at 8:30 …

Lifecore Signs Six New Programs, Including Two Commercial-Stage

Lifecore Biomedical reported Q2 2026 revenues of $34.2 million, a 6.2% decrease year-over-year, and a net loss of $6.2 million. Despite the revenue decline, the company reaffirmed its 2026 guidance for revenues of $120–$125 million and Adjusted EBITDA of $20.5–$25 million, citing strong business …

Lifecore Biomedical (NASDAQ: LFCR) Q2 revenue slips as 2026 guidance reaffirmed

Lifecore Biomedical reported a decline in Q2 2026 revenue to $34.2 million and an increased net loss of $6.2 million, despite growth in hyaluronic-acid manufacturing. The company reaffirmed its full-year 2026 guidance for revenue ($120-$125 million) and Adjusted EBITDA ($20.5-$25 million), highlighting a strong …

BioCryst Starts Shipping ORLADEYO Oral Pellets to Pediatric Patients

BioCryst Pharmaceuticals reported strong Q2 2026 financial results, with total revenue up 34% year-over-year to $218.3 million and ORLADEYO revenue reaching $158.2 million. The company has begun shipping ORLADEYO oral pellets to pediatric HAE patients and raised its full-year total revenue guidance while lowering …

Kamada sets Aug. 12 call to discuss first-half results

UNITED THERAPEUTICS ($UTHR) Releases Q2 2026 Earnings

United Therapeutics Q2 2026 earnings: Lower taxes lift EPS as revenue slips

Press Release: United Therapeutics Corporation Reports Second Quarter 2026 Financial Results

United Therapeutics Corporation announced its financial results for the second quarter of 2026. The report details the company's financial performance, likely including revenue, net income, and earnings per share, for the specified period. This press release provides key insights into the company's operational and …

(ELAN) Elanco Animal Health Expects 2026 Revenue Range $5.09B - $5.14B, vs. FactSet Est of $5.07B

Elanco Animal Health (ELAN) announced its revenue expectations for 2026, forecasting a range of $5.09 billion to $5.14 billion. This projection surpasses the current FactSet estimate of $5.07 billion. The company also reported Q2 adjusted earnings and revenue increases, leading to an updated 2026 …

(ELAN) Elanco Animal Health Incorporated Expects Q3 Revenue Range $1.20B - $1.22B

Elanco Animal Health Incorporated (ELAN) announced its Q3 revenue expectations, projecting a range of $1.20 billion to $1.22 billion. This follows their Q2 adjusted earnings and revenue rise, which led to an increase in their 2026 outlook, with revenue expected between $5.09 billion and …

Elanco Q2 2026 earnings: Innovation demand lifts revenue and margins

Elanco Animal Health reported strong Q2 2026 earnings, with revenue up 10% to $1.368 billion and GAAP EPS rising significantly due to demand for innovative pet health products and global ruminant portfolio growth. The company raised its full-year guidance for revenue, adjusted EBITDA, and …

Elanco’s (NYSE:ELAN) Q2 CY2026: Strong Sales, Stock Soars

Elanco (NYSE: ELAN) reported stronger-than-expected Q2 CY2026 results, with revenue of $1.37 billion, a 10.2% year-on-year increase, and non-GAAP EPS of $0.34, significantly beating analyst estimates. The animal health company also raised its full-year revenue and adjusted EPS guidance, indicating positive momentum in the …

Elanco raises 2026 outlook after Q2 revenue climbs 10%

Elanco Animal Health (ELAN) reported strong Q2 2026 results with revenue up 10% year over year to $1.368 billion, and net income rising significantly. Following this performance, the company has raised its full-year 2026 financial outlook, including revenue and adjusted EPS guidance, and increased …

Scynexis Ongoing Deadline Alert

Faruqi & Faruqi, LLP is investigating potential claims against SCYNEXIS, Inc. (NASDAQ: SCYX) and reminds investors of the January 8, 2024, deadline to seek the role of lead plaintiff in a federal securities class action. The investigation stems from allegations that Scynexis made false …

Net income $607.9M and $1.5B buyback at United Therapeutics (NASDAQ: UTHR)

Lifecore Biomedical, Inc. Reaffirms Earnings Guidance for the Calendar Year 2026

Lifecore Biomedical, Inc. has reaffirmed its earnings guidance for the calendar year 2026, expecting revenue to be in the range of $120 million to $125 million. This announcement was made on August 5, 2026, coinciding with their Q2 2026 earnings call. The company specializes …

Roth Capital Initiates Alpha Teknova at Buy With $7 Price Target

Roth Capital has initiated coverage of Alpha Teknova (TKNO) with a Buy rating and set a price target of $7. This indicates a positive outlook from the investment bank on the company's future stock performance.

Earnings To Watch: Alpha Teknova Inc (TKNO) Q2 2026 -- GF Value Sees 24% Downside

Alpha Teknova Inc (TKNO) is preparing to release its Q2 2026 earnings, with revenue expected to hit $10.97 million and earnings at $-0.08 per share. While analyst estimates show an average price target implying a significant upside, GuruFocus's GF Value suggests a 24% downside …

Dr. Reddy's Laboratories Ltd $RDY Shares Purchased by Quantinno Capital Management LP

Roth/MKM initiates Alpha Teknova stock with buy rating on growth outlook

Roth/MKM has initiated coverage on Alpha Teknova Inc. (NASDAQ:TKNO) with a Buy rating and a $7.00 price target, citing the company's strong growth prospects and high customer retention. The firm highlighted Alpha Teknova's differentiated customizable solutions for the life sciences sector and the potential …